tirzepatide 台灣 上市 猛健樂（Mounjaro，成分名：Tirzepatide） 也就是台灣俗稱的「縮胃針」進階版或是「瘦瘦筆」的新一代王者。, 它之所以比之前的明星藥物（如 Ozempic/Wegovy，成分為 Semaglutide）更有效，核心原因在於它是全球首款**「雙重受體激動劑」**。, 如果把上一代的減肥藥比喻為「單引擎」飛機，猛健樂就是裝載了**「雙渦輪引擎」**的噴射機。以下是它如此有效的科學原理解析 雙效腸泌素（猛健樂）（Mounjaro）（Tirzepatide）終於來了– 瑞東診所

With strong Phase IIb results already in hand and the molecule now advancing to global Phase III, theyre optimistic about bringing this oral option to India once the data and regulatory approvals align

3 Coupled with the metabolic benefits of this drug, the Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) trial showed a 20% reduction in major cardiovascular events with Semaglutide, making it the only weight loss medication to do so

It complemented the functional readouts, strengthening evidence that this model leads to real but subclinical hepatic impacts worthy of further mechanistic investigation

That scale gives the paper visibility and makes it harder to dismiss, even if the final message remains cautious

2013;2014(129):S10238

As emerging evidence builds, providers must balance potential benefits with safety concerns and patient-specific factors